132 related articles for article (PubMed ID: 15688600)
1. Reversing resistance to targeted therapy.
Vidal L; Attard G; Kaye S; De Bono J
J Chemother; 2004 Nov; 16 Suppl 4():7-12. PubMed ID: 15688600
[TBL] [Abstract][Full Text] [Related]
2. [Resistance to target-based therapy and its circumvention].
Nishio K
Nihon Rinsho; 2004 Jul; 62(7):1343-7. PubMed ID: 15283154
[TBL] [Abstract][Full Text] [Related]
3. [The mechanisms of the resistance to molecular targeting agents].
Akiyama S
Nihon Rinsho; 2004 Jul; 62(7):1297-304. PubMed ID: 15283147
[TBL] [Abstract][Full Text] [Related]
4. [Molecular targeted therapy].
Stenner-Liewen F; Zippelius A; Pestalozzi BC; Knuth A
Chirurg; 2006 Dec; 77(12):1118-25. PubMed ID: 17109101
[TBL] [Abstract][Full Text] [Related]
5. [Molecular target therapy for malignant tumors].
Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():76-80. PubMed ID: 15796061
[No Abstract] [Full Text] [Related]
6. Dissecting kinase signaling pathways.
Boyle SN; Koleske AJ
Drug Discov Today; 2007 Sep; 12(17-18):717-24. PubMed ID: 17826684
[TBL] [Abstract][Full Text] [Related]
7. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
Kim R; Toge T
Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442
[TBL] [Abstract][Full Text] [Related]
8. An overview of targeted treatments in cancer.
Abou-Jawde R; Choueiri T; Alemany C; Mekhail T
Clin Ther; 2003 Aug; 25(8):2121-37. PubMed ID: 14512124
[TBL] [Abstract][Full Text] [Related]
9. Beyond Herceptin and Gleevec.
Fischer OM; Streit S; Hart S; Ullrich A
Curr Opin Chem Biol; 2003 Aug; 7(4):490-5. PubMed ID: 12941424
[TBL] [Abstract][Full Text] [Related]
10. [Targeted drugs in radiation therapy].
Favaudon V; Hennequin C
Cancer Radiother; 2004 Nov; 8 Suppl 1():S114-20. PubMed ID: 15679256
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate.
Waller CF
Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
[TBL] [Abstract][Full Text] [Related]
12. [The new mechanisms and reversal of drug resistance].
Akiyama S
Gan To Kagaku Ryoho; 2003 Jan; 30(1):1-8. PubMed ID: 12557697
[TBL] [Abstract][Full Text] [Related]
13. [Problems in the current target therapy of malignancies].
Stukov AN; Gershanovich ML; Filov VA; Imianitov EN
Vopr Onkol; 2005; 51(5):607-11. PubMed ID: 16756022
[No Abstract] [Full Text] [Related]
14. [Cardiac toxicity and edema].
Takeuchi S; Sakai H
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1654-8. PubMed ID: 18931565
[TBL] [Abstract][Full Text] [Related]
15. Methodological aspects of current problems in target-based anticancer drug development.
Yamanaka T; Okamoto T; Ichinose Y; Oda S; Maehara Y
Int J Clin Oncol; 2006 Jun; 11(3):167-75. PubMed ID: 16850122
[TBL] [Abstract][Full Text] [Related]
16. HER2 as a target for breast cancer therapy.
Tagliabue E; Balsari A; Campiglio M; Pupa SM
Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497
[TBL] [Abstract][Full Text] [Related]
17. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
Becker JC; Muller-Tidow C; Serve H; Domschke W; Pohle T
World J Gastroenterol; 2006 Jun; 12(21):3297-305. PubMed ID: 16733844
[TBL] [Abstract][Full Text] [Related]
18. Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
Jabbour E; Cortes J; Kantarjian H
Oncology (Williston Park); 2007 May; 21(6):653-62; discussion 663-4, 667-8. PubMed ID: 17564324
[TBL] [Abstract][Full Text] [Related]
19. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.
Rochat B
Clin Pharmacokinet; 2005; 44(4):349-66. PubMed ID: 15828850
[TBL] [Abstract][Full Text] [Related]
20. Lung cancer: not just for smokers. People who never smoked may have a different form of the disease that responds better to a new generation of targeted medications.
Harv Health Lett; 2007 Jan; 32(3):4-5. PubMed ID: 17323498
[No Abstract] [Full Text] [Related]
[Next] [New Search]
